G
GeneDx Inc
Delivering personalized and actionable health insights that inform diagnosis, direct treatment, and improve drug discovery
About GeneDx Inc
GeneDx is a pioneering company in the field of clinical genomics and rare disease diagnostics. The company specializes in genetic testing, which involves analyzing a patient's DNA to identify changes or mutations that could be linked to various health conditions. GeneDx serves a diverse range of clients, including patients, families, and healthcare providers, who rely on its expertise to gain deeper insights into genetic disorders.
Operating in the healthcare and biotechnology market, GeneDx has established itself as a leader by sequencing more than 300,000 clinical patient exomes. An exome is the part of the genome that contains genes, which are crucial for understanding genetic diseases. The company uses advanced techniques to collect DNA samples from cheek swabs, blood, or other specimens. These samples are then sequenced to detect genetic variations. The results are analyzed by a team of technical and clinical experts, and a detailed report is sent back to the healthcare provider.
GeneDx's business model revolves around providing rapid and accurate genetic testing services. They offer products like GenomeXpress and XomeDx Xpress, which deliver results in as little as seven days. This quick turnaround is vital for critical cases where timely diagnosis can significantly impact treatment outcomes, reduce hospital stays, and lower healthcare costs.
The company generates revenue by charging for its genetic testing services. Healthcare providers, hospitals, and clinics pay for these tests to diagnose and manage genetic conditions in their patients. Additionally, GeneDx offers digital Patient Letters, which provide personalized genetic information to patients and their families, enhancing their understanding of the test results.
In summary, GeneDx is at the forefront of clinical genomics, offering rapid and reliable genetic testing services that cater to patients, families, and healthcare providers. Their innovative approach and deep clinical expertise make them a key player in the personalized medicine landscape.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2000
- Headquarters
- Gaithersburg, United States
- Listing
- IPO 2020
- Employees
- 1,261
- Open positions
- 29
- Dealroom signal
- 94.9/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Became $1B as Subsidiary, Biotech and Pharma, Became Thoroughbred as Subsidiary, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
- Investment activity
- 1 company, latest May 2025
- Capital deployed
- —
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITYOther financing | May 2026 | $43M | — | Prosight Management | ↗ |
| DEBTDebt | Mar 2026 | $100M | — | Undisclosed | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $428M | 0% | $13M | 3.1% |
| 2025 | $428M | +40% | $13M | 3.1% |
| 2024 | $305M | +50.8% | $12M | 4% |
| 2023 | $203M | -13.7% | −$127M | -62.8% |
| 2022 | $235M | +10.6% | −$396M | -168.6% |
| 2021 | $212M | +18.3% | −$424M | -200% |
| 2020 | $179M | — | −$227M | -126.7% |
Growth signals
Latest recorded traffic for GeneDx Inc is 79K monthly website visits, up 23.4% over the last three months. GeneDx Inc's team grew 51.2% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later2 investors entered at this stage
Perceptive Advisors- PMProsight Management
Other known investors2 additional known investors
National Institutes of Health
Sema4
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about GeneDx Inc on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See GeneDx Inc’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.